ArticleDiabetes, obesity & metabolism2026
Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimTo quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in France and Spain, using a discrete choice experiment (DCE). MATERIALS AND
methodsA targeted literature review and qualitative patient interviews informed an attributes and levels grid consisting of six attributes (2-3 levels each). Pilot interviews were conducted to test the DCE. A quantitative DCE survey was administered to adults with T2D in France and Spain. Hierarchical Bayesian estimation was used to identify the relative importance of each attribute.
resultsThe survey was completed by N = 239 participants from France (n = 166) and Spain (n = 73) across three treatment experience categories: basal insulin and injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) naïve (n = 86), basal insulin naïve but injectable GLP-1 RA experienced (n = 85), and basal insulin experienced (n = 68). Frequency of administration had a relative importance of 39%, nearly double that of the attribute with the next highest relative importance 'risk of severe hypoglycemic event (insulin experienced rates)' (21%). A preference for once weekly (OW) administration was observed relative to once daily (OD) or twice daily (BD). Reduction in the frequency of missing doses and taking doses at the prescribed time were considered the most positive impacts of OW administration. Findings were consistent across treatment experience groups.
conclusionThis study highlights the importance of administration frequency in basal insulin treatment decisions when glycemic control is held constant. Participants indicated a preference for OW injection frequency, suggesting fewer injections may reduce the burden of insulin administration. These insights support clinical consideration of less frequent injections when making T2D treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.